PCN105 Economic Evaluation of Panitumumab and Cetuximab in the Treatment of Patients with EGFR Expressing mCRC with Non-Mutated (Wild-Type) KRAS in Gree A Cost Minimization Analysis
Abstract
Authors
V. Fragoulakis V. Papagiannopoulou G. Kourlaba P. Ducournau N. Maniadakis